EMN Live: The October 2017 Issue
Dr. Pescatore and Ms. Roberts discuss the game-changers and hot topics in the October issue, like Dr. Leon Gussow’s article on how opioids aren’t only drugs that are abused, Dr. Carlo Reyes’ article on why EPs should be federally protected from violence bu patients, why Dr. James Roberts’ next piece is game-changer for treating PID, how Dr. Christine Butts makes diagnosing ovarian torsion is easier with ultrasound, and how Drs. Adam Rodos and Wes Eilbert explain how to reverse NOACs. That plus bonus interviews with Dr. Roberts about PID and Dr. Ken Milne about evidence-based medicine. (Source: Everyday Medicine for Physicians)
Source: Everyday Medicine for Physicians - September 20, 2017 Category: Emergency Medicine Authors: Emergency Medicine News Emergency Medicine News Source Type: podcasts
New Data Address Critical Surgical Questions in Ovarian Cancer
At ASCO 2017, two trials tackled important surgical questions in ovarian cancer management, with the potential to eventually change practice, according to Dr Maurie Markman. (Source: Medscape Oncology)
Source: Medscape Oncology - August 4, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Bradley J. Monk, MD, FACS, FACOG - New Horizons in Managing Advanced Ovarian Cancer: Diagnostic Strategies, Novel Therapies, and Patient-Centered Treatment Decisions
New Horizons in Managing Advanced Ovarian Cancer: Diagnostic Strategies, Novel Therapies, and Patient-Centered Treatment Decisions (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - July 31, 2017 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
A New Standard for Low-Grade Serous Cancer of the Ovary?
Dr Maurie Markman discusses new research on therapy for low-grade serous cancer of the ovary from the Journal of Clinical Oncology. (Source: Medscape Oncology)
Source: Medscape Oncology - June 29, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Longevity of Ovarian Function and Risk for Heart Failure
Dr Andrew Kaunitz discusses hormone receptor therapy in menopausal women and the relationship between ovarian function duration and risk for heart failure. (Source: Medscape Cardiology Podcast)
Source: Medscape Cardiology Podcast - June 8, 2017 Category: Cardiology Authors: Medscape Source Type: podcasts
Longevity of Ovarian Function and Risk for Heart Failure
Dr Andrew Kaunitz discusses hormone receptor therapy in menopausal women and the relationship between ovarian function duration and risk for heart failure. (Source: Medscape ObGyn Podcast)
Source: Medscape ObGyn Podcast - June 8, 2017 Category: OBGYN Authors: Medscape Source Type: podcasts
Use of Mirvetuximab Soravtansine for Platinum-Resistant Epithelial Ovarian Cancer Patients
Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of his current clinical studies, which focus on the use of mirvetuximab so...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Genomic and Psychosocial Characteristics of Long Term Survivors in Ovarian Cancer
Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center discusses a collaborated study with Dr. Dr. Jalid Sehouli of AGO and Charit Campus Virchow-...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
What is the Difference between CA4P and Other Anti-Angiogenesis Agents?
Krishnansu S. Tewari, MD of University of California, Irvine explains the different between the new drug CA4p and other anti-angiogenesis agents in ovarian cancer. This was recorded at the 2017 ASCO A...
Author: ASCO2017
Added: 06/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 2, 2017 Category: Cancer & Oncology Source Type: podcasts
FOCUS Trial: CA4P in Patients with Platinum Resistant Ovarian Cancer (prOC)
Krishnansu S. Tewari, MD of University of California, Irvine gives an overview of the FOCUS trial, which is sponsored by Mateon Therapeutics. The FOCUS trial is a double-blind, randomized, phase 2/3 c...
Author: ASCO2017
Added: 06/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 2, 2017 Category: Cancer & Oncology Source Type: podcasts
FOCUS Trial Gives Patients Another Option for Treatment
Krishnansu S. Tewari, MD of University of California, Irvine discusses the impact of the FOCUS trial on clinical practice, explaining how the trial gives ovarian cancer patients another option for tre...
Author: ASCO2017
Added: 06/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 2, 2017 Category: Cancer & Oncology Source Type: podcasts
